How a 19-Year Patent on an Old Drug Redefines Pharma Strategy

WEST CONSHOHOKEN, PA – July 28, 2026 – A seemingly routine press release from two specialty pharmaceutical companies, PRM Pharma and Ingenus Pharmaceuticals, has unveiled one of the most elegant commercial strategies I’ve seen this year. The news? The U.S. Food and Drug Administration has listed a new patent for HemiClor®, their version of a decades-old hypertension drug, in its coveted “Orange Book.” On the surface, it’s regulatory minutiae. But look closer, and you’ll see a blueprint for how to build a fortress of value in a market everyone else thought was commoditized.

The announcement secures intellectual property protection for their unique 12.5 mg chlorthalidone tablet until 2045. This isn’t just about a drug; it’s about a brilliant patent play that locks out generic competition for nearly two decades, demonstrating how niche innovation can outmaneuver a market dominated by giants.

The Patent Play: Building a Moat Around a Commodity

To understand the significance of this move, one must first understand the FDA’s Orange Book. It’s the definitive list of approved drugs and their related patents. Getting a patent listed in the Orange Book is like engraving your company’s name on a shield. Under the Hatch-Waxman Act, any company wanting to launch a generic version of HemiClor must now confront and challenge this specific patent, a costly and time-consuming legal battle. By securing this listing, PRM and Ingenus have effectively raised a drawbridge that will remain up until 2045.

What makes this so compelling is that chlorthalidone is not a new drug. It’s a workhorse diuretic that has been used to treat high blood pressure for over 60 years. Generic versions of its higher doses (25 mg and 50 mg) are widely available and inexpensive. The market, for all intents and purposes, was mature and commoditized. So how do you create new value? You don’t invent a new molecule; you perfect the delivery.

HemiClor is the first and only FDA-approved 12.5 mg tablet of chlorthalidone. The patent, U.S. Patent No. 12,667,554 B1, doesn’t protect the drug itself, but the proprietary formulation technology required to make this specific low-dose tablet stable, effective, and manufacturable at scale. It’s a classic case of innovation hiding in plain sight, transforming a simple dosage adjustment into a formidable intellectual property asset.

Precision Dosing: Why 12.5 Milligrams Matters

The business strategy is only viable because it’s built on a solid clinical foundation. The move to a 12.5 mg dose isn’t arbitrary; it’s a direct response to where medical science is heading. Major clinical guidelines, including those from the American College of Cardiology and the American Heart Association (ACC/AHA), now recognize lower doses of diuretics like chlorthalidone as an optimal starting point for many patients with hypertension.

Research has shown that a 12.5 mg dose can achieve a significant portion of the blood-pressure-lowering effects of a 25 mg dose, but with a substantially lower risk of side effects like electrolyte imbalances. Before HemiClor, physicians who wanted to follow these guidelines had to ask patients to split 25 mg tablets—an inexact practice that leads to inconsistent dosing and can compromise the tablet's stability. HemiClor eliminates this issue, providing a precise, guideline-aligned dose in a single, stable pill. This is where consumer demand for precision and efficacy meets pharmaceutical innovation.

As Joe McDevitt, President and CEO of PRM Pharma, stated, "HemiClor demonstrates that meaningful innovation remains possible even for well-established medicines." He noted that the lower dose could mitigate dose-related side effects, a critical factor for patients who will be on the medication for life. This isn't just about reformulating a drug; it's about refining a therapy to better fit the needs of the modern patient and the standards of modern medicine.

The Niche Innovator's Blueprint

The story of HemiClor is the story of the modern specialty pharmaceutical company. PRM Pharma and Ingenus Pharmaceuticals aren’t trying to discover the next blockbuster molecule. Instead, they operate with a different playbook: identify unmet needs within established markets, apply sophisticated science to solve a practical problem, and use the regulatory and patent systems to protect their solution.

Ingenus, the developer and patent owner, tackled the complex technical hurdles of creating a low-dose tablet. Mukteeshwar Gande, the inventor of the technology, explained the challenge: "Developing a commercially robust 12.5 mg chlorthalidone tablet required much more than reducing the dose." The team had to overcome issues with dissolution, particle characteristics, and stability—the unglamorous but essential work of pharmaceutical science. Their success resulted in the patent that now forms the core of HemiClor’s value.

PRM Pharma, as the marketer, then guided this innovation through the FDA’s 505(b)(2) regulatory pathway. This savvy route allows a company to rely in part on the FDA's previous findings of safety and efficacy for an existing drug, dramatically streamlining the approval process. The combination of deep formulation science, a clever regulatory strategy, and a strong patent defense is the trifecta that allows these smaller players to carve out highly profitable niches.

This model provides a powerful counter-narrative to the idea that pharmaceutical innovation only happens in the labs of Big Pharma. It suggests that immense value can be created by looking at old problems with new eyes and applying targeted expertise. For investors and strategists, this is the key takeaway: the future of commercial success may lie not in inventing the new, but in perfecting the old.